105+ total transactions representing $1B+ in aggregate value — 13 tracked below spanning 2020–2026 · 2 industries
Provided fairness opinion for Applied Therapeutics on acquisition by Cycle Pharmaceuticals. Applied focused on ultra-rare genetic diseases; deal integrated Applied's pipeline into Cycle's specialized rare disease franchise.
Exclusive financial advisor to Adverum on the sale of the company and its lead gene therapy candidate (Ixo-vec) for Phase 3 wet age-related macular degeneration. Deal included upfront payment plus CVR contingent on FDA approval and commercial milestones.
Financial advisor to AmacaThera on exclusive global licensing agreement with Pacira for tunable drug delivery platform. Deal includes upfront payment, milestones, and royalties.
Engaged as financial advisor to Movano Health's Board of Directors for process to maximize shareholder value. Movano is a digital health/wearable medical device company.
Strategic advisor on $1B+ option and license agreement with Novartis for oral covalent IRAK4 inhibitors. Structured partnership including upfront payments, milestones, and royalties.
Strategic advisor on $2.1B+ global collaboration agreement with Sanofi to develop and commercialize IRAK4 protein degrader therapies.
Financial advisor on sale of ALZET product line (osmotic drug delivery pumps) to Lafayette Instrument for $17.5M cash. Transaction enabled DURECT to refocus capital and extend cash runway.
M&A advisor on sale of single-cell spatial biology tools company to Takara Bio USA. Curio's platform enabled spatial transcriptomics for research.
Strategic advisor on option and license agreement with AbbVie for $400M+ to develop and commercialize reproxalap for ophthalmology.
M&A advisor on sale of NGS library preparation genomics kits company to Danaher/IDT. Swift Bioscience provided research tools for genomics laboratories.
M&A advisor to Protomer Technologies on strategic acquisition by Eli Lilly. Protomer developed protein engineering technology.
Financial advisor on Series B financing of $20.7M for PreciseDx. Placement included venture capital and strategic investors for AI-powered cancer risk assessment platform.